Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0002024096-25-000003
Filing Date
2025-10-17
Accepted
2025-10-17 19:28:16
Documents
1
Period of Report
2025-10-15

Document Format Files

Seq Description Document Type Size
1 form4-10172025_111011.html 4  
1 form4-10172025_111011.xml 4 7467
  Complete submission text file 0002024096-25-000003.txt   8921
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Issuer) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O LEXEO THERAPEUTICS, INC. 345 PARK AVENUE SOUTH, FLOOR 6 NEW YORK NY 10010
Business Address
Otero Jose Manuel (Reporting) CIK: 0002024096 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-41855 | Film No.: 251402095